Dr. Alderuccio is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1475 Nw 12th Ave
Miami, FL 33136Phone+1 305-243-6608Fax+1 305-243-4975
Summary
- I am a board-certified Hematologist-Oncologist, and I specialize in the treatment of patients diagnosed with lymphoma. I also conduct clinical research focused on expanding the treatment repertoire for patients diagnosed with various lymphomas.
My research efforts are geared toward improving and expanding the treatment options available for patients diagnosed with both aggressive and indolent lymphomas. In particular, I am interested in the development of novel, targeted therapies which hinges on the use of genetic sequencing technology. My current research is aimed at identifying clinical characteristics in patients with marginal zone lymphoma in an attempt to distinguish those prone to a worse outcome, as well as a higher risk for transformation to an aggressive lymphoma. Furthermore, I am also involved in studies integrating PET/CT data in the risk stratification of lymphoma patients, with the goal of developing strategies for individualize care.
Education & Training
- University of Miami/Jackson Health SystemFellowship, Hematology and Medical Oncology, 2014 - 2017
- New York Medical College (Metropolitan)Residency, Internal Medicine, 2011 - 2014
Certifications & Licensure
- FL State Medical License 2017 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Clinical Investigator Career Development Award Lymphoma Research Foundation, 2022
- FDA-AACR Oncology Educational Fellowship FDA and AACR, 2021-2022
- K12 Calabresi Clinical Oncology Research Career Development Award NCI, 2019-2021
Clinical Trials
- Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma Start of enrollment: 2022 Feb 11
Roles: Sponsor-Investigator, Contact, Principal Investigator
Publications & Presentations
PubMed
- 13 citationsSplenic marginal zone lymphoma: A US population‐based survival analysis (1999‐2016)Jorge A. Florindez, Juan Pablo Alderuccio, Isildinha M. Reis, Izidore S. Lossos
Cancer. 2020-11-01 - 46 citationsRisk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single InstitutionJuan Pablo Alderuccio, Wei Zhao, Amrita Desai, Nicolas Gallastegui, Jeremy Ramdial
Journal of Clinical Oncology. 2018-10-12 - 6 citationsMutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.David A Russler-Germain, Kilannin Krysiak, Cody Ramirez, Matthew Mosior, Marcus P Watkins
Blood Advances. 2023-09-26
Abstracts/Posters
- Splenic Marginal Zone Lymphoma: A U.S Population-Based Survival Analysis (1997-2016)Juan Pablo Alderuccio, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...Juan Pablo Alderuccio, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)Juan Pablo Alderuccio, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Omission of Staging Bone Marrow Biopsy Does Not Affect Outcomes in Patients with Stage I Extranodal Marginal Zone Lymphoma (EMZL) Treated with Radiation Therapy61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- R-MACLO-IVAM Is an Effective Regimen to Induce Long Term Remission in Untreated Mantle Cell Lymphoma61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Revised-MALT-IPI: A New Predictive Model That Identifies High-Risk Patients with Extranodal Marginal Zone Lymphoma (EMZL)61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Join now to see all
Press Mentions
- Sylvester Cancer Researchers Share Findings in Oral Presentations at the ASH 2024 Annual Meeting & Exposition - Tip SheetNovember 13th, 2024
- Sylvester Cancer Researchers Share Findings in Oral Presentations at the ASH 2024 Annual Meeting & Exposition – Tip SheetNovember 13th, 2024
- BostonGene and Sylvester Comprehensive Cancer Center at the University of Miami Announce CollaborationMay 23rd, 2023
- Join now to see all
Committees
- Member, Protocol Review and Monitoring Committee 2021 - Present
- Member, American Society of Hematology Committee on Educational Affairs
Professional Memberships
- Member
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: